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Abstract. Aim: To evaluate vascular morphology and density,
angiogenic switch activation, vascular endothelial growth factor
(VEGF) expression, and endothelial cell (EC) proliferation in
the hamster cheek pouch (HCP) model of oral cancer. Materials
and Methods: Immunohistochemical detection of factor VIII, 5’-
Bromo-2’-Deoxyuridine (BrdU) and VEGF was performed in
pre-malignant and tumoral tissues. Results: Activation of
angiogenesis was detected adjacent to epithelial dysplasia.
Vascularized area and perimeter (p<0.001) increased in
dysplasias and tumors. Tumor blood vessels exhibited an
enhanced vascular compression (p<0.001) and structural
alterations. EC proliferation was similar in dysplasias and
carcinomas. An increase in vascular density, EC proliferation
and VEGF expression was found in potentially malignant
tissues but not in carcinomas. Conclusion: The angiogenic
switch occurs in the dysplastic stage preceding tumor
development in the HCP model of oral cancer. In potentially
malignant tissues, increased VEGF expression favors EC
proliferation and an increase in vascular density. Conversely, in
tumors, VEGF is no longer of pivotal importance. 
Angiogenesis, the formation of new blood vessels by
sprouting or bridging from pre-existing vessels, is crucial for
normal development and growth but it is also essential in
pathological conditions, such as tumor growth. Angiogenesis
precedes tumor formation during chemically-induced
carcinogenesis, suggesting that tumor progression depends
on a switch from a pre-vascular to a vascular phase (1). The
first report on the angiogenic potential of pre-malignant
lesions was provided by Folkman et al., when the induction
of angiogenesis during the transition from hyperplasia to
neoplasia was demonstrated (1, 2). The time when the
quiescent vasculature becomes activated to grow new
capillaries is the so-called angiogenic switch (3-5) The
angiogenic switch involves the ability of the tumor and its
microenvironment to secrete angiogenic factors that
stimulate proliferation and migration of endothelial cells
(ECs) of the host to form new vessels that provide nutrients
and oxygen. Signals that trigger the angiogenic switch
include metabolic stress (i.e. that produced by hypoxia),
genetic mutations (6) and, mainly, the increase in
proangiogenic mediators such as fibroblast growth factor
(FGF) or vascular endothelial growth factor (VEGF). VEGF
is a major proangiogenic factor, well-documented as
inducing vascular EC proliferation and vascular sprouting
(7). It has been demonstrated that VEGF receptors are
present on tumor cells themselves and other cells from the
tumor microenvironment, in addition to tumoral ECs (8).
VEGF is expressed in vascular ECs and a range of non-ECs
including hematopoietic stem cells, macrophages, monocytes
and osteoclasts (9-10). The contribution of VEGF to the
development of oral dysplasia and invasive carcinomas is not
perfectly understood (11). Several studies have demonstrated
the expression of VEGF in normal epithelium, potentially
malignant lesions and squamous cell carcinoma SCC in
human oral mucosa. Whereas some authors have found no
correlation between VEGF expression and angiogenesis in
human oral dysplasia or carcinoma (12-15), possibly because
tumor angiogenesis is mediated by other factors in addition
to VEGF (16), other studies have found that an increase in
microvessel density (MVD) correlates with an increase in
VEGF expression in oral squamous cell carcinoma (17, 18).
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Moreover, Gandolfo et al. reported that leukoplakia exhibited
an increase in VEGF expression and in sub-epithelial
vascularization in human oral mucosa, and that this increase
was significantly greater in leukoplakia with dysplastic
changes than in leukoplakia without dysplasia (19).
According to Folkman (20) the number and structure of
tumor-associated blood vessels, the expression of pro- and
anti-angiogenic molecules and specific receptors reflects
tumor angiogenic potential. In addition, it must be noted that
increased proliferation of ECs in blood vessels can induce
sprouting of new vessels, with a concomitant increase in
vessel density in tissue, or alternatively, only result in
increased diameter of pre-existing vessels (21).
In terms of vascular morphology, studies have demonstrated
that blood vessels begin to show abnormalities, such as
increased vascular density, dilation and hyperpermeability, are
collapsed or have incomplete perivascular cell coverage as early
as in the hyperplastic/ dysplastic stage (22). Once tumors have
arisen, tumor blood vessels do not respect the hierarchy of
arterioles, capillaries and venules of the vascular network.
Instead, they exhibit a disorderly pattern, are irregular and leaky,
generally hemorrhagic and tortuous, and form plexuses that
resemble disorganized coils (23). There is also evidence of the
existence of ‘mosaic-blood vessels’ in tumors: their wall is
partially composed of ECs and tumor cells that are incorporated
during the neoangiogenesis that precedes tumor formation (24).
The hamster cheek pouch (HCP) model of carcinogenesis
is the most widely accepted model of oral cancer. The pouch
lies within the cheek and is lined by malpighian epithelium.
Topical application of the carcinogen 7,12-dimethylbenz
[a]anthracene (DMBA) (25-27) induces the phenomenon of
field cancerization, similarly to tobacco and alcohol in human
mucosa (28). Potentially malignant lesions and squamous cell
carcinomas that histologically resemble human carcinomas
coexist in the same pouch. As the model recapitulates field
cancerization, it is possible to analyze the epithelial changes
that occur from a cancerized epithelium with no unusual
microscopic findings (NUMF) to hyperplasia, varying degrees
of dysplasia, and finally to invasive carcinoma. In this way, by
studying phenomena that occur in the connective tissue
underlying these potentially malignant lesions it is possible to
assess the vascular changes that take place during the process
of carcinogenesis. The changes that occur in the
microvasculature during the sequential progression of
epithelial cancerization have not been fully-characterized, to
date, in the HCP. 
Our laboratory has previously reported the expression of
FGF2 in potentially malignant lesions, as well as in tumors
of the HCP (29). We found an increased FGF2 expression in
early stages of carcinogenesis, while tumors showed a slight
or no expression at all, of this growth factor. The potentially
malignant lesions and the tumors expressed FGF receptors 2
and 3. Studies have been performed in the HCP to study
angiogenesis (30, 31) but as far as we are aware of, no
studies have been performed to assess the changes in
microvasculature during carcinogenesis in this model. 
The aim of the present study was to contribute to the
characterization of the HCP model of oral cancer, focusing
on the similarities to and differences from the process of
human oral carcinogenesis. Within this context, the study
involved: a) Determination of the point at which the
angiogenic switch takes place in the HCP; b) assessment of
the potential correlation between VEGF, MVD and
proliferation of ECs in potentially malignant lesions and
tumors of the HCP; c) analysis of the changes in vascular
morphology throughout the process of experimental
carcinogenesis in the HCP.
Materials and Methods 
Tumor induction. The right cheek pouch of 10 non-inbred young (6
weeks old) Golden Syrian hamsters (Breeding Facility, National
Atomic Energy Comission, Ezeiza, Buenos Aires, Argentina) was
subjected to topical application of 0.5% DMBA (SIGMA-
ALDRICH, Inc., St. Louis, MO, USA) in mineral oil three times a
week for 14 weeks in keeping with a standard HCP carcinogenesis
protocol (25). Once the tumors had developed (approximately at 11
to 14 weeks), the animals were euthanized according to the NIH
Laboratory Animals Guide Care, and the protocol was approved by
the Ethics Committee of the University of Buenos Aires. The 10
hamsters developed a total of 14 tumors that were studied herein.
Eight normal, non-DMBA-treated hamsters were used as controls.
Thirty minutes prior to sacrifice 2 ml of a 1% solution of 5-bromo-
2’deoxyuridine (BrdU) in distilled water (approximately 0.2 g
BrdU/kg b.w.) was administered i.p. to each hamster. After sacrifice,
the pouches were everted, dissected and fixed in 10% formalin in
phosphate buffered saline (PBS) (pH 7.0). Specimens containing
tumors and premalignant tissue were paraffin-embedded.
Histology and immunohistochemistry. Sections (7 μm-thick) were
H&E stained for routine histopathology. Adjacent 12 μ-thick
sections were used for immunohistochemical demonstration of
VEGF and BrdU (32).
Pilot studies were performed with commercial antihuman
antibodies to CD31, CD34, CD105, factor VIII and wheat germ
lectins to determine the best blood vessel label in hamster tissues
(data not shown). Of all the markers studied, factor VIII proved to
be the best for visualizing vascular walls in the HCP. 
Histopathology: Areas of cancerized epithelia with NUMF, areas
of hyperplasia, dysplasia and carcinoma were identified in keeping
with pre-established criteria (33, 34)
Immunohistochemical labeling of factor VIII: Endogenous
peroxidase activity was blocked with 100% H2O2 in methanol.
Sections were then transferred to PBS (pH 7.4). After antigen
unmasking by protease digestion with proteinase K 10% in PBS and
permeabilization of tissue with chilled acetone at −20˚C for 10 min
[modified from Tonar et al. (35). Sections were incubated in a
polyclonal rabbit antibody to human von Willebrandt Factor (vWF)
(DAKO Cytomation, High Wycombe, Surrey, UK) at a dilution of
1/4000 overnight at room temperature. After washing with PBS-
albumin, the sections were incubated using the biotin-streptavidine-
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peroxidase kit (Multilink Kit; Biogenex, San Ramon, CA, USA):
secondary antibody (biotinylated anti-Ig in PBS with carrier protein
and preservative) for one hour at room temperature, sections where
washed with PBS and then incubated with tertiary antibodie
(peroxidase-conjugated streptavidin in PBS with carrier protein and
preservative) for one hour at room temperature The slides were then
incubated with 3,3-diaminobenzidine (DAKO Cytomation),
counterstained with hematoxylin and mounted. 
Immunohistochemical labeling of VEGF: Endogenous peroxidase
activity was blocked with 100% H2O2 in methanol for 30 min. After
antigen unmasking by citrate buffer (pH 4) in a microwave oven at
maximum power for 5 min, sections were incubated with a primary
antibody against human VEGF raised in goat (VEGF-147, 200 μg/ml;
Santa Cruz Biotechnology Inc., California; USA) at a dilution of 1:20 in
PBS overnight at room temperature. After washing with PBS-albumin,
the sections were incubated with the secondary and tertiary antibodies
(secondary antibody) (biotinylated anti-Ig in PBS with carrier protein
and preservative) for one hour at room temperature, sections where
washed with PBS and then incubated with tertiary antibodies
(peroxidase-conjugated streptavidin in PBS with carrier protein and
preservative) for 1 h at room temperature using the biotin-streptavidine-
peroxidase kit (Multilink Kit; BIOGENEX Laboratories). The slides
were then incubated with 3,3-diaminobenzidine (DAKO Cytomation),
counterstained with hematoxylin and mounted. A section from a single
block of normal human kidney was mounted on each slide to serve as a
positive control and for grading the intensity of the reaction (36).
Immunohistochemical detection of cells synthesizing DNA:
Following antigen retrieval with 0.1 M citrate buffer (pH 6) in a
microwave oven, sections were incubated in mouse monoclonal
antibody to BrdU (clon IIB5; Biogenex) overnight at 4˚C After
washing with PBS-albumin, the sections were incubated with the
secondary and tertiary antibodies (secondary antibody) (biotinylated
anti-Ig in PBS with carrier protein and preservative) for one hour at
room temperature, sections where washed with PBS and then
incubated with tertiary antibodies (peroxidase-conjugated
streptavidin in PBS with carrier protein and preservative) for 1h at
room temperature using the biotin-streptavidine-peroxidase kit
(Multilink Kit; BIOGENEX Laboratories). The slides were then
incubated with 3,3-diaminobenzidine (DAKO Cytomation), counter-
stained with hematoxylin and mounted. 
MVD assessment in potentially malignant lesions. Vascular sections
identified by the endothelial expression of factor VIII were counted
at ×400 magnification using a grid fitted into the light microscope
eyepiece. One section was assessed per case. Vessel sections were
counted in the pouch wall along all the sub-epithelial connective
tissue between the basal membrane and the subjacent muscle layer.
All the subepithelial connective tissue available in the section was
evaluated, correlating each area with the overlying epithelial
alteration: NUMF, hyperplasia or dysplasia. 
Analysis of vessel morphology in potentially malignant lesions and
tumors. To study vessel morphology associated with the different
epithelial lesions, digital images of the vascular sections
immunostained for factor VIII were taken. Vessels were hand-traced
employing the ImageJ image analysis software (version 1.43,
National Institutes of Health; http://rsb.info.nih.gov/ij/), as described
by Padera et al. (37) and Hagendoorn et al. (22). The parameters
area, perimeter and aspect ratio (AR) were calculated. AR was
considered an indicator of degree of vascular compression in
keeping with the criteria of Hagendoorn et al. (22). AR is defined as
the ratio between the maximum and minimum axes. An AR of 1
indicates that the vessel section is a perfect circle (major
diameter=minor diameter), that there is no compression of the
vessel, and that perfusion is optimum. Conversely, when the section
deviates from a perfect circle, the AR will increase as the difference
between the major and minor diameters widens, indicating a high
degree of compression and alterations in vascular perfusion. 
Analysis of VEGF immunohistochemical labeling. VEGF was
quantified in 10 random fields of potentially malignant epithelium
adjacent to tumors in each section and in 10 random fields of
tumor stroma using a magnification of ×400. Immunostaining was
scored from 0 to 2: 0 as negative or less intense than kidney
control; 1 as moderate or equal to the control; 2 as intense or
stronger than the control.
Counts of proliferating ECs. EC proliferation in blood vessels was
evaluated as a function of BrdU incorporation. BrdU analysis of
ECs was limited to vessels with open lumina. BrdU-positive nuclei
in ECs were identified in control, potentially malignant lesions and
tumor tissue sections based on their morphological protrusion into
the vessel lumen. All the ECs present in the connective tissue
available in control pouches (n=8), in the connective tissue
underlying potentially malignant lesions (n=11), and in the stroma
of tumors (n=14) were analyzed. 
Statistical analysis. The data are reported as the mean±SD. Statistical
analysis was performed by ANOVA and Tukey’s test for comparisons
a posteriori. Statistical significance was set at p<0.05 using the Primer
of Biostatistic Statistical Analysis Program (Copyright 1992, McGraw
Hill, Inc., Version 3.02 by Stanton A. Glantz).
Results 
Factor VIII immunostaining and MVD assessment. Immuno-
staining for factor VIII exhibited a positive and homogeneous
reaction in all the blood vessel walls in normal and pre-
malignant tissues (NUMF, hyperplasia and dysplasia), whereas
tumor blood vessels exhibited patchy and fainter labeling.
Factor VIII preparations revealed that compared with normal
epithelium, the MVD was significantly increased in the
connective tissue underlying dysplastic lesions (p<0.05)
(Figure 1). Carcinomas, on the other hand, contained a lower
percentage of vessels compared to dysplasias. (MVD evaluated
in different areas is compared in Table I).
EC proliferation. EC nuclei with positive staining (BrdU-
positive ECs) exhibited brown diaminobenzidine deposits
that contrasted with unlabeled blue, hematoxylin-stained
nuclei. Analysis of proliferating ECs in vessels revealed an
increase in BrdU-positive ECs in dysplasias (5.46±9.66
BrdU-positive ECs per field n=11) and in carcinomas
(6.49±6.66 BrdU-positive ECs per field n=14) compared to
control endothelia where no proliferation was observed (38)
(n=8) (p<0.05). Importantly, the proliferation of ECs was
similar in dysplasias and carcinomas .
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To determine whether increased proliferation of ECs in
blood vessels yielded sprouting of new vessels or only
resulted in an increased diameter of pre-existing vessels, we
assessed the correlation between blood vessel perimeter at
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Figure 1. Factor VIII immunostaining reflecting the angiogenic switch in
the connective tissue underlying dysplastic epithelium (×400). 
Figure 2. Immunolabeling of factor VIII showing the progressive
increase in area and perimeter from control pouch (A), to connective
tissue underlying dysplastic epithelium (B) and tumor stroma (C)
(×400). 
Figure 3. Progressive increase in vascular area (A) and perimeter (B) in
areas underlying dysplastic epithelium and tumor stroma compared to
vessels in control pouches. The aspect ratio was increased in connective
tissue underlying dysplasias and tumor blood vessels compared to
controls (C). *p<0.05 Compared to the control. Data are the mean±SD.
Table I. Number of blood vessels/mm2 of sub-epithelial connective tissue
underlying different tissue areas.
Tissue area Blood vessels/mm2
Normal epithelium (n=11) 85.08±48.32
NUMF (n=6) 58.08±25.46
Hyperplasia (n=6) 108.63±96.11
Dysplasia (n=5) 182.63±104.8***
Tumor (n=8) 68.43±64.43
***Dysplasia significantly different from normal epithelium at p<0.05.
each stage and MVD, as reported by Eichteen et al. (21). We
found that blood vessel perimeter significantly increased
concomitantly with the progressive development of
alterations of the overlying epithelia to yield carcinoma
(Figure 3A). We found a significant increase in the number
of blood vessels at the dysplastic pre-malignant stage, but in
carcinomas, the number of blood vessels was lower, although
not significant, compared to dysplastic tissue (Table I). In
summary, blood vessels increased in perimeter and density
in potentially malignant tissue but in tumors, vessels
increased only in perimeter without an increase in density,
thus reflecting increased sprouting of new blood vessels
(classic angiogenesis) in potentially malignant tissue as
opposed to increased diameter without sprouting of vessels
in tumors.
Analysis of vascular morphology variations in potentially
malignant lesions and tumor tissue. A progressive increase
in area and perimeter from control pouch to connective
tissue underlying dysplastic epithelium and tumor stroma
was determined (p<0.05) (Figures 2 and 3A and B). The
AR was significantly increased in vessels underlying
dysplasia compared with control (p<0.05) and in vessels of
tumor stroma compared with dysplasia (p<0.05) (Figures
3C and 5). A significant fraction of tumor vessels had
collapsed lumens and in some cases, the tumor vessels
formed tangled clumps, exhibiting a disorderly glomerular-
like structure. Some tumor blood vessel walls displayed
areas composed of ECs alternating with areas composed of
tumor cells. 
Immunohistochemical expression of VEGF. Normal
epithelium exhibited moderate VEGF staining but this was
lower than that in the kidney used as a positive control of the
labeling technique. VEGF staining was scored as moderate-
to-intense in potentially malignant lesions adjacent to tumors
(1.69±0.63), with no differences between staining in NUMF,
hyperplasias and dysplasias. However, VEGF expression in
carcinomas was significantly lower than in potentially
malignant lesions (0.33±0.60; p<0.05) (Figure 4).
Discussion
In the present study, we found an increase in MVD
associated with dysplastic lesions, concomitantly with a rise
in the expression of the angiogenic factor VEGF. These data,
together with the increased proliferation of ECs in dysplastic
lesions, would indicate that the angiogenic switch precedes
tumor development in the HCP and that the switch would
thus appear to occur in the dysplastic stage. 
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Figure 4. Immunolabeling with antibody against VEGF. Normal oral mucosa (A). A stronger reaction was found in potentially malignant epithelium
(B) and a less intense reaction in tumor parenchyma (C) (×400).
Figure 5. Significant increase in aspect ratio (difference between the
major and minor diameters widens) in vessels underlying dysplasias
compared to controls (p<0.05) and in vessels of tumor stroma compared
to dysplasias (p<0.05).
ECs in quiescent tissues divide approximately once every
two to three years if unstimulated (38). During cancer
development, it is well established that the local tissue level
of the proangiogenic factor VEGF increases and enhances
proliferation of vascular ECs and the sprouting of new blood
vessels from pre-existing vascular beds (2). The present
study showed an increase in vascular density in dysplasia,
associated with an increase in the proliferation of ECs and
an increase in VEGF expression in potentially malignant
tissue. Conversely, Denhart et al. (39), found that normal or
mildly dysplastic oral epithelium expressed no VEGF, whilst
moderately dysplastic epithelium had a low level of VEGF
expression. Carlile et al. (12)found no difference between
VEGF expression in normal oral mucosa when compared to
epithelial dysplasia, indicating that any increase in dysplasia
is not accompanied by an increase in VEGF expression. In
potentially malignant tissue in the HCP, the increase in
VEGF probably favors the proliferation of ECs and an
increase in vascular density. In our study, in carcinomas,
vascular density did not rise, VEGF expression decreased
and EC proliferation was similar to that of dysplasia but did
not increase further. This would indicate that in tumor in the
HCP, the role of proangiogenic factors is no longer pivotal
since ECs would proliferate in response to factors of the
tumor microenvironment. 
In the HCP, a mild inflammatory reaction takes place in the
first days of topical application of the carcinogen. After this,
there is no inflammatory process in the pouch and therefore
none of the epithelial and connective tissue changes observed
in the present analysis are related to inflammatory response.
It is a fact that blood vessels undergo distinct
architectural alterations during neoplastic progression (22).
These alterations include classic angiogenic changes in EC
proliferation, and in vessel diameter, density, and leakage
(23). Hagendoorn et al. revealed alterations in blood
vasculature, architectural changes, and impairment of
lymphatic vessels along with increased interstitial fluid
pressure in premalignant tissues (22). Our data for the HCP
indicate that during squamous carcinogenesis, the blood
vessels underlying dysplastic lesions exhibit an increase in
density and perimeter, suggesting that the blood flow that
reaches the tissue that is on the verge of developing into
tumor is greater than in normal tissue. In addition, the
blood vessels underlying dysplasia and the vessels of tumor
stroma exhibited an increase in area and perimeter, as well
as an evident compression, which would correlate with
reduced and altered vascular perfusion (22). The presence
of vessels with collapsed lumens, or with a tangled,
disorderly, glomerular-like pattern in tumors would suggest
inadequate perfusion and poor tumor tissue nutrition. There
is enough evidence in the literature of the increase in
vascularity in carcinomas and potentially malignant
disorders of human oral mucosa (40-46, 19). Knowledge of
the angiogenic activity of a potentially malignant lesion of
the epithelium is clinically relevant within the context of
the biological behaviour of these epithelia. Gandolfo et al.
reported that leukoplakia exhibited an increase in VEGF
expression and in sub-epithelial vascularization (19). This
increase was significantly greater in leukoplakia with
dysplastic changes than in leukoplakia without dysplasia.
The epithelia of leukoplakia without dysplasia can remain
as such for a long time, less frequently reverting to a
normal epithelium or, much less frequently, evolving
towards more aggressive lesions. However, dysplastic
lesions are considered to have a higher risk of malignant
transformation. This issue is of direct practical value for the
evaluation of lesion prognosis. 
The vascular changes that take place during HCP
carcinogenesis have been observed in different experimental
contexts (29-31). However, to date, a characterization of the
sequence and degree of those changes throughout the process
of carcinogenesis was lacking. The knowledge of these
changes is essential when the model is used to assess anti-
angiogenic therapies. In our laboratory in particular, this
knowledge has been pivotal in studying the effect of boron
neutron capture therapy (BNCT) on the vasculature of pre-
malignant and malignant tissues in the HCP. BNCT is a
binary cancer treatment modality that combines irradiation
with a thermal or epithermal neutron beam with boron-10
carriers that are taken up preferentially by neoplastic cells.
High linear energy transfer alpha particles and recoiling 7Li
nuclei are emitted during the capture reaction. These
particles have a range of 5-9 μm in tissue and are known to
have a high relative biological effectiveness. In this way,
BNCT potentially targets tumor tissue selectively, mostly
sparing normal tissue (47)
In addition, the characterization of vascular changes
throughout the process of carcinogenesis is necessary for
other studies-in-progress at our laboratory that involve tumor
blood vessel ‘normalization’ in order to improve the efficacy
of BNCT. Certain anti-angiogenic agents, mostly anti-VEGF
agents, can transiently ‘normalize’ the abnormal structure and
function of tumor vasculature to make it more efficient for
oxygen and drug delivery. Drugs that induce vascular
normalization can alleviate hypoxia and increase the efficacy
of conventional therapies if both are carefully scheduled
(48). If one were to judiciously down-regulate VEGF
signaling in tumors, then the vasculature might revert back
to a more ‘normal’ state. Indeed, blockade of VEGF
signaling passively prunes the immature and leaky vessels of
transplanted tumors in mice and actively remodels the
remaining vasculature so that it more closely resembles the
normal vasculature. This ‘normalized’ vasculature is
characterized by less leaky, less dilated, and less tortuous
vessels, with a more normal basement membrane and greater
coverage by pericytes. These morphological changes are
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accompanied by functional changes, such as lower interstitial
fluid pressure, increased tumor oxygenation, and improved
penetration of drugs in these tumors (48).
It is known that for BNCT to be effective, boron targeting
of all tumor cells is pivotal and tumor blood vessel
normalization improves drug delivery to tumors in the HCP
(49). Within this context, tumor blood vessel normalization
would improve tumor boron targeting and subsequently,
BNCT efficacy. 
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